Y-Biologics, Inc. (KOSDAQ:338840)

Market Cap	525.92B +357.9%
Revenue (ttm)	3.61B -31.0%
Net Income	-8.73B
EPS	-668.31
Shares Out	15.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	204,477
Average Volume	292,322
Open	35,100
Previous Close	35,600
Day's Range	33,550 - 36,500
52-Week Range	5,330 - 38,000
Beta	2.51
RSI	69.10
Earnings Date	n/a

About Y-Biologics

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 338840

Financial Performance

In 2024, Y-Biologics's revenue was 5.76 billion, an increase of 65.64% compared to the previous year's 3.48 billion. Losses were -6.44 billion, -69.14% less than in 2023.